Ye Kuang

Featured in: Favicon

businessinsider.com Favicon

msn.com

nature.com Favicon

wiley.com

mdpi.com

acs.org

benzinga.com Favicon

rsc.org

hindawi.com Favicon

newsbreak.com + 7 more

Articles

Efficient Nitrate Formation in Fog Events Implicates Fog Interstitial Aerosols as Significant Drivers of Atmospheric Chemistry

Nov 21, 2024 | dx.doi.org | Wanyun Xu |Ye Kuang |Weiqi Xu |li Liu

Occurrence, Fate, and Transport of Contaminants in Indoor Air and AtmosphereNovember 21, 2024 Wanyun Xu State Key Laboratory of Severe Weather & Key Laboratory for Atmospheric Chemistry, Institute of Atmospheric Composition, Chinese Academy of Meteorological Sciences, Beijing 100081, China * Ye Kuang Institute for Environmental and Climate Research, College of Environment and Climate, Jinan University, Guangzhou 511443, China *Email: [email protected] Weiqi Xu State Key Laboratory of...
The Impact of Agroecosystems on Nitrous Acid (HONO) Emissions during Spring and Autumn in the North China Plain

Apr 30, 2024 | mdpi.com | Jianhui Zeng |Wanyun Xu |Ye Kuang |Weiqi Xu

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
Multi-omic analyses of m5C readers reveal their characteristics and immunotherapeutic proficiency - Scientific Reports

Jan 17, 2024 | nature.com | Ye Kuang

Abstract5-methylcytosine (m5C) is a post-transcriptional RNA modification identified, m5C readers can specifically identify and bind to m5C. ALYREF and YBX1 as members of m5C readers that have garnered increasing attention in cancer research. However, comprehensive analysis of their molecular functions across pancancer are lacking. Using the TCGA and GTEx databases, we investigated the expression levels and prognostic values of ALYREF and YBX1.
Why Sana Biotechnology Shares Are Trading Higher Today

Apr 13, 2023 | benzinga.com | Ye Kuang

Sana Biotechnology SANA shares are trading higher after the company announced the publication of a paper in Nature Communications on hypoimmune-modified allogeneic CD19-directed CAR T cells. The paper reports the efficacy of HIP CAR T cells in killing tumors in both immunocompetent and immunodeficient models of humanized mice. The study found that HIP CAR T cells were equally effective in clearing tumors in both models and were not prone to exhaustion.
Why Regulus Therapeutics Shares Are Trading Higher Today

Apr 13, 2023 | benzinga.com | Ye Kuang

Regulus Therapeutics RGLS shares are trading higher on Thursday after the company announced a $15 million private placement of equity. The company today announced that it has signed a securities purchase agreement for a private placement to specific institutional and accredited investors. Under the agreement, the investors will buy 2,615,536 shares of Regulus Therapeutics' common stock at $0.9001 per share.
Why Is SAB Therapeutics Stock Trading Higher Today?

Apr 13, 2023 | benzinga.com | Ye Kuang

SAB Therapeutics SABS shares are trading higher on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high cross-reactivity to multiple strains of influenza. SAB-176 is an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.
Why InMode Shares Are Trading Higher Today

Apr 12, 2023 | benzinga.com | Ye Kuang

InMode Ltd. INMD shares are trading higher on Wednesday after the company issued Q1 guidance. According to the guidance, InMode expects Q1 revenue of $105.7 million - $105.9 million, non-GAAP EPS of $0.50 - $0.51, and non-GAAP gross margin to be between 83% and 85%. Members of InMode's management team are planning to hold a conference call on Tuesday, May 2, at 8:30 a.m to discuss the company's financial results for the first quarter of 2023.
Why Panbela Therapeutics Shares Are Trading Higher Today

Apr 12, 2023 | benzinga.com | Ye Kuang

Panbela Therapeutics PBLA shares are trading higher on Wednesday after the company announced the first patient has been enrolled in the Phase II trial of CPP-1X-T. CPP-1X, also known as eflornithine, is being developed as a single agent tablet or high dose powder sachet for various indications, including prevention of gastric cancer, treatment of neuroblastoma, and recent onset Type 1 diabetes.
Why Is Creative Medical Technology Stock Skyrocketing Today?

Apr 12, 2023 | benzinga.com | Ye Kuang

Creative Medical Technology CELZ shares are trading higher on Wednesday after the company announced one-year follow-up data and significant efficacy using CELZ-001 to treat patients with Type 2 Diabetes without any serious adverse effects reported. The use of CELZ-001 in a one-year follow-up study, with the same infusion procedure as the currently US FDA-cleared CELZ-201 clinical trial, did not raise any safety concerns.
What's Going On With Moderna Stock Today?

Apr 11, 2023 | benzinga.com | Ye Kuang

Moderna MRNA shares are trading lower on Tuesday after the company said its first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the independent DSMB recommended continuation of efficacy follow-up. mRNA-1010 is the Company's first vaccine candidate against influenza, which is being developed in adults. mRNA-1010 is currently being evaluated in two Phase 3 trials.